The CGTLive™ Hematology specialty topic page houses the most up-to-date clinical news coverage in the field of hematology gene and cell therapy. It also includes video interviews with key opinion leaders in the field of hematology/oncology about the latest relevant FDA actions, clinical guideline updates, and clinical trial findings related to the development of cell therapies, gene therapies, and engineered and regenerative medicines for various blood disorders.
September 15th 2024
The company also discontinued its other clinical programs as well, which included small molecule and monoclonal antibody modalities.
8th Annual School of Nursing Oncology™
View More
Crucial Conversations in R/R Multiple Myeloma: Nursing Strategies to Optimize Patient Communication and Improve Outcomes
View More
Oncology Briefings™: Coordinating the Long-Term Management of Patients With Multiple Myeloma Between Primary Care and Oncology Practices
View More
Community Practice Connections™: Illuminating the Crossroads of Precision Medicine and Targeted Treatment Options in AML
View More
GlobaOncology Town Hall™: Primary Investigators Present Key Abstracts in the Management of B-Cell Lymphomas with BTK Inhibitors
View More
Community Practice Connections: 7th Annual School of Nursing Oncology™
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
Oncology Consultations®: Community and Academic Perspectives on PNH Management – How Do You Do It?
View More
Community Oncology Connections™: Overcoming Clinical Challenges and Embracing New Opportunities in the Management of Multiple Myeloma
View More
Cases and Conversations™: Applying Guidelines to Practice for the Management of Paroxysmal Nocturnal Hemoglobinuria
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Oncology Briefings™: Selecting Therapy for Patients with Heavily Pretreated Myeloma Based on Patient and Disease-Specific Factors
View More
Community Practice Connections™: How Can We Optimize the Real World Application of BCMA-Targeted Therapies for Our Patients with R/R Multiple Myeloma?
View More
Oncology Briefings™: Case Discussions in Smoldering Myeloma—To Treat or Not to Treat?
View More
Medical Crossfire®: How Has the Nurse’s Role Evolved in the Management of Pediatric Patients With Neurofibromatosis Type 1 and Plexiform Neurofibromas?
View More
Annual Hematology Meeting: Preceding the 66th ASH Annual Meeting and Exposition
December 6, 2024
Register Now!
Oncology Town Hall™: Primary Investigators Present Key Abstracts in CLL from San Diego
View More
Focusing on Key Updates on the Outlook of Acute Lymphocytic Leukemia (ALL) Management
View More
Understanding the Recent Developments in Myelodysplastic Syndromes (MDS)
View More
Experts Address the Hottest Topics in AML: Considerations on FLT3, IDH1/2, TP53, Maintenance, Novel Combinations and Beyond!
View More
Medical Crossfire®: Novel BTKi Strategies Transforming Aggressive and Indolent B-Cell Malignancies
View More
Experts Address the Hottest Topics in AML: Considerations on FLT3, IDH1/2, TP53, Maintenance, Novel Combinations and Beyond!
View More
Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat
View More
Medical Crossfire®: Bridging Expert Guidance and Evidence-Based Recommendations in the Treatment of AYA and Adult ALL
View More
Medical Crossfire®: Novel BTKi Strategies Transforming Aggressive and Indolent B-Cell Malignancies
View More
Medical Crossfire®: Bridging Expert Guidance and Evidence-Based Recommendations in the Treatment of AYA and Adult ALL
View More
Real-World Applications of Asparaginase Formulations in ALL and LBL From Pediatric/AYA to Adult Treatment: Maximizing Clinical Benefits Through Multidisciplinary Care
View More
Putting Your Stamp on the Next Generation of Care in CML — Improving Outcomes from Frontline to R/R Treatment Settings
View More
The Latest Advancements in the Treatment of Chronic Myeloid Leukemia (CML)
View More
EHA Preview: Advances, Outcomes in CAR T-Cell Therapies and Management Challenges
June 8th 2021With 5 chimeric antigen receptor (CAR) T-cell therapies approved by the FDA, and 299 agents in the pipeline, it’s no surprise that the virtual meeting of the European Hematology Association (EHA) will have a heavy presence of CAR T research being presented in sessions and posters.
Etranacogene Dezaparvovec Is Highly Unlikely the Cause of HCC in Hemophilia B Study
March 29th 2021Etranacogene dezaparvovec was "highly unlikely" to be the cause of hepatocellular carcinoma in a patient with hemophilia B enrolled in the phase 3 HOPE-B trial, according to an independent investigation.
FDA Approves Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma
March 27th 2021The FDA has approved idecabtagene vicleucel as the first BCMA-directed CAR T-cell therapy for patients with relapsed/refractory multiple myeloma after 4 or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.
AB-205 Eliminates SRRTs With HDT-AHCT for Lymphoma
March 16th 2021AB-205 showed an encouraging safety profile along with a robust ability to eliminate oral and gastrointestinal severe regimen-related toxicities in patients with systemic lymphoma who were undergoing high-dose therapy and autologous hematopoietic stem cell transplantation.